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Abstract 
Background: The prevalence of allergies and the incidence of cancer are both increasing worldwide. It has been 
hypothesized that atopy may affect the risk of some cancers.
Methods: In this study, 1525 patients (754 women and 771 men with a mean age of 52.7 ± 11.9 years) with differ-
ent types of cancer were examined for the presence of allergies. Allergies were confirmed based on retrospective 
analysis of allergy diagnostic procedures in patients previously diagnosed with cancer. All patients were also analyzed 
for bronchial asthma and allergic rhinitis according to relevant guidelines. A control group of patients without cancer 
diagnoses was used for comparison.
Results: Patients with cancer had significantly fewer IgE-mediated allergic diseases than the control population. For 
the oncological group compared to the non-cancer patients, the odds ratios (ORs) for allergic rhinitis, atopic dermati-
tis, and bronchial asthma were 0.67 (95 % CI 0.52–0.81), 0.89 (95 % CI 0.78–0.99), and 1.03 (95 % CI 0.91–1.13), respec-
tively. The mean serum concentrations of total IgE were significantly lower in the study population of patients with 
cancer than in the patients in the control group (45.98 ± 14.9 vs. 83.2 ± 40.1 IU/l; p < 0.05). There were no significant 
correlations between the type of cancer diagnosed and the form of allergy.
Conclusion: Our results indicate that the overall incidence of allergies, particularly allergic rhinitis, was lower in 
patients with some types of cancer. Further studies are needed to confirm our findings.
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Background
The worldwide increased prevalence of cancer has 
impacted attempts to search for factors that may play 
roles in promoting or protecting against oncogenesis [1, 
2]. Among other approaches, efforts have been made to 
search for correlations between different chronic dis-
eases, e.g., between allergies and the induction of can-
cer [3, 4]. The possibility of a promoting or protective 
role of allergy in cancer has been an interesting research 
topic over the years. There have been various hypoth-
eses regarding the impact of IgE-mediated allergies 
and the occurrence of cancer [3]. One hypothesis pro-
posed a protective function for atopies against cancer 
via immunosurveillance [5–7]. The overstimulation of 
immunocompetent cells as a result of contact with an 
allergen causes the production of certain IgE antibodies 
that may have a cytotoxic influence on cancer cells [5, 7]. 
A second hypothesis proposed a relationship between 
atopy and an increased risk of cancer incidence, stem-
ming from the prolonged stimulation of the immunologi-
cal system by chronic inflammation [5, 7]. A continuous 
and chronic infection accompanied by an allergy may 
induce the production of free oxygen radicals, which 
may encourage oncogenesis [3, 5, 7]. Another hypothesis 
involves prophylaxis. The physical effects of allergic reac-
tions in some tissues may clear mutagenic triggers before 
malignant transformations can occur. Finally, another 
recent hypothesis suggested that inappropriate T-helper 
2 immune skewing is possible [8].
Despite a large number of studies, no clear answer 
regarding the validity of one hypothesis over another 
has been determined. Retrospective epidemiological 
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observations dominate the literature [6, 9–11]. Most pro-
spective studies have only evaluated self-reported allergy 
histories and risks of cancer [12, 13]. Only a few studies 
have estimated allergies in patients with cancer based on 
the results of an allergy diagnosis (i.e., total IgE measure-
ments and skin prick tests) [14, 15].
The incidence of allergies based on retrospective 
allergy diagnostic documentation in patients diagnosed 
with cancer and comparisons with a normal population 




Patients were recruited from eight oncological outpatient 
clinics in southern Poland. The patient databases from 
each site were analyzed. A total of 9800 medical records 
were prescreened, and 3200 patients were randomly 
selected with the following confirmed diagnoses: breast, 
lung, colon or skin cancer. The sampled study population 
was designed to be representative of the most common 
cancers with respect to typical age and sex in Poland in 
2014. From this group, only 1856 patients have to fulfill 
the following additional inclusion criteria: over 35 years 
of age and having undergone basic oncological treat-
ment (i.e., chemotherapy, radiotherapy and/or surgery) 
that was finished a minimum of 1 year prior to the study. 
From this group of patients, 244 patients were excluded 
from further analysis due to a lack of detailed documen-
tation, and 87 were excluded due to a lack of consent 
(exclusion criteria).
In the end, 1525 patients comprising 754 women and 
771 men aged 35–80  years were analyzed. This group 
included 247 patients with lung cancer, 211 patients 
with colon cancer, 231 patients with breast cancer and 
199 patients with skin cancer. The mean time of can-
cer disease duration was 4.3 ±  2.9  years, and the mean 
time after basic treatment was 2.7 ± 1.8 years. All types 
of cancer were previously diagnosed based on clini-
cal symptoms, imaging tests (e.g., X-ray, CT, MRI, PET, 
endoscopy, and USG), biopsies, serum measurements, 
cancer markers and the ICD-10 code.
Control group
A control group was formed from a screening of 10,200 
medical records from a medical database of GP in the 
same region of Poland with an age and sex distribution 
similar to that of the study group. The control group was 
randomly selected to maintain similar proportions as 
those found in the study group. A total of 3100 subjects 
were randomly selected. The inclusion criteria for the 
control group were as follows: over 35 years of age and a 
lack of cancer diagnosis or clinical suspicion.
In total, 1689 subjects were pre-enrolled. The same 
exclusion criteria were applied as in the study group: lack 
of detailed documentation (n = 103) and lack of patient 
consent (n  =  42). Finally, 1544 subjects were analyzed. 
The group comprised 754 women and 790 men, aged 
35–82 years.
The population details are presented in Table 1.
Allergy data
Total serum IgE concentration and specific IgE con-
centration were analyzed in response to the following 
allergens: Dermatophagoides pteronyssinus, D. farinae, 
Aspergillus fumigatus, Alternaria tennis, Cladosporium 
herbarum, dog, cat, grass mix, birch, alder, hazel, and 
mugwort. IgE values greater than 0.35 kU/l were consid-
ered positive.
Skin-prick tests against the mentioned inhalant aller-
gens were also analyzed. The tests were evaluated accord-
ing to previously published guidelines [16].
Allergic rhinitis was confirmed based on the following 
medical documentation: laryngological examinations, 
and history of clinical symptoms according to ARIA 
guidelines [17]. Bronchial asthma was confirmed by 
documentation of clinical symptoms according to GINA 
guidelines and spirometry data and/or positive results 
from reversibility tests or positive results from metha-
choline tests in accordance with the criteria of ATS and 
ERS [18]. Atopic dermatitis was recognized from derma-
tological examinations and from criteria defined by Hani-
fin and Rajka [19].
Statistical analysis
All results are presented as the mean ± SD or as a per-
centage. Differences between groups were assessed using 
the Kruskal–Wallis test. The odds ratio was calculated for 
disease occurrence. A value of p  <  0.05 was considered 
significant for all analyses. Statistica 8.1 was used for the 
analysis (StatPol, Cracow, Poland).






Percentage of women 49.4 48.8
Mean age (years) 52.7 ± 11.9 50.5 ± 12.4
Smoking-current or past (%) 1115 (73.1) 689 (44.6)
Higher education 368 (24.1) 450 (29.1)
Living in rural area 412 (27.1) 471 (30.5)
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Results
Patients with the analyzed types of cancer had a slightly 
but significantly lower risk of IgE-mediated allergic dis-
eases than those in the control population. The odds 
ratio of a clinical manifestation of any allergy (i.e., allergic 
rhinitis, conjunctivitis, atopic dermatitis, and bronchial 
asthma) in patients diagnosed with the analyzed types of 
cancer was 0.76 (95  % CI 0.63–0.84) compared to non-
cancer patients. The risk differed depending on the type 
of allergic disease. The odds ratios for each type of allergy 
were 0.67 (95  % CI 0.52–0.81) for allergic rhinitis, 0.89 
(95 % CI 0.78–0.99) for atopic dermatitis and 1.03 (95 % 
CI 0.91–1.13) for bronchial asthma. This trend was inde-
pendent of the type of analyzed cancer with the exception 
of breast cancer, for which the prevalence of all allergic 
diseases was the same as for the controls. The details are 
shown in Fig. 1 and Table 2.
There were no significant differences in the allergen 
profiles of the analyzed allergic patients in the cancer and 
control groups. However, in both groups, allergies to D. 
pteronyssinus (38.5 % of the study population with cancer 
vs. 34.2 % of control group), D. farinae (31.4 vs. 30.4 %) 
and grass pollen (24.9 vs. 22.1 %) were predominant.
The mean serum concentration of total IgE was signifi-
cantly lower in the study population than in the control 
group (45.98 ± 14.9 vs. 83.2 ± 40.1 IU/l; p < 0.05), and an 
inverse correlation with cancer incidence was observed. 
The positive results of analyzed allergen-specific IgEs in 
allergic patients were comparable between the study and 
control groups. Based on the skin testing results, IgEs to 
D. pteronyssinus, D. farinae and grass pollen were pre-
dominant in both groups.
Cancer, allergy and socioeconomic factors
Low socioeconomic status (financial problems, low edu-
cation, smoking, and alcohol use) was related to cancer 
diagnosis. High levels of education have been linked to 
allergies. Identical trends of SEP were observed for lung 
and colon cancer (p  <  0.05); however, breast and skin 
cancer were dependent only on smoking (p < 0.05). There 
were positive correlations between patient age and diag-
nosis of all types of cancer (p  <  0.05). The influence of 
socioeconomic factors on the incidence of cancer, allergy 
or their combination is presented in Table 3.
Discussion
The results support the hypothesis of a general inverse 
association between cancer diagnoses and predisposi-
tion to allergies. However, this relationship appears to be 
complex.
The serum concentration of total IgE was inversely 
correlated with cancer diagnoses. However, there was 
no correlation between positive results for inhalant 
allergen-specific IgEs and the overall cancer incidence. 
Cohort studies have confirmed such a link between total 
serum IgE and cancer presence. However, these studies 
analyzed somewhat different types of populations, i.e., 
patients without initial cancer diagnoses and with only 
self-reported allergies [11, 14, 20]. Of course, cohorts 
provide more relevant insights, but case control stud-
ies allows an analysis of larger quantities of data (for 
example, the results of diagnostic procedures) due to 
Fig.1 The occurrence of allergic disease in patients with cancer. 
ANN chronic allergic rhinitis, SAR sporadic, allergic rhinitis, AD atopic 
dermatitis *p < 0.05
Table 2 Percentage of  patients with  allergic diseases 
among those with cancer and in the control group
NS not significant, AR chronic allergic rhinitis, SAR sporadic, allergic rhinitis, AD 
atopic dermatitis
a Lung cancer, b Colon cancer, c Breast cancer, d Skin cancer
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their smaller study populations. The present study is 
also unique in this European region, which is impor-
tant because of the different life style of the analyzed 
patients, which influences the prevalence of allergies 
and cancers.
The protective role of IgE against carcinogenesis was 
confirmed by Van Hemelrijck et  al. [11]. By contrast, 
Skaaby et al. did not support this hypothesis based on a 
study of atopy and cancer prevalence in approximately 
15,000 patients [21]. Skaaby et al. also noted an associa-
tion between atopy and a lower risk of dying for breast 
cancer but not for cancer in general [22]. This study high-
lighted the lack of a simple link between atopy and the 
risk of not only neoplasms but also other chronic dis-
eases [22]. These results further support the complexity 
of this relationship.
We confirmed that sporadic or chronic allergic rhini-
tis was significantly less prevalent in patients with breast, 
colon, pulmonary or skin cancer diagnosis. Similar trends 
between asthma and atopic dermatitis were not deter-
mined. It is known that various types of cancers could 
exhibit different associations with atopic disease. With 
respect to the prevalence of allergic rhinitis, some studies 
have confirmed an increase in allergic rhinitis in patients 
with lung cancer and a lack of association with hema-
tological malignancies [3, 23, 24]. However, as found in 
the present work, Turner et al. [4, 25] observed a similar 
reduction in the incidence of intermittent allergic rhinitis 
in patients diagnosed with colorectal cancer.
The obtained data do not indicate a significant rela-
tionship between the analyzed types of cancer and the 
occurrence of atopic dermatitis. In contrast, an increased 
or decreased risk of melanoma or non-melanoma can-
cer in patients with atopic dermatitis was confirmed by 
other researchers [3, 9]. Despite the high concentrations 
of IgE in this disease, atopic dermatitis is a more hetero-
genic disease than allergic rhinitis and also has non-aller-
gic associations (e.g., autoimmunological and infectious 
diseases).
In a case–controlled study with 3300 incident can-
cer diagnoses in males from Canada, eczema was found 
to be less prevalent in patients with cancer [12]. Similar 
observations were confirmed in a few other studies; how-
ever, these studies typically focused on only single types 
of cancer, e.g., gliomas [13]. Unfortunately these cancer 
types were not analyzed in the present study.
Bronchial asthma is often considered a disease, par-
ticularly with respect to cancer. The patients of the study 
population with lung cancer did not have a greater inci-
dence of asthma compared with the patients of the con-
trol group. However, a few studies have reported that 
the presence of cancer is either positively or negatively 
correlated with asthma [3, 12, 26]. Most studies on this 
relationship have included only small groups of patients 
and have only explored single types of cancer. The results 
obtained herein did not examine whether any specific 
type of inhaled allergy would be more or less favorable in 
inducing cancer. However, the overproduction of IgE may 
represent a yet to be determined correlation. The possi-
bility of misclassification of COPD or overlap syndrome 
(COPD and asthma) during data analysis may also have 
affected the final results for the odds ratio for asthma in 
the studied patients.
Additionally, analysis of socioeconomic (SEP) factors 
confirmed earlier observations that patients with can-
cer exhibit lower SEP, and the additional coexistence of 
allergies did not alter this trend in the present study [27]. 
Higher education and male sex were correlated with the 
presence of atopic disease, consistent with the observa-
tions of a previous study on a Danish population [28]. By 
contrast, links between atopy and smoking, drinking and 
BMI were not confirmed by our observations. The atypi-
cal nature and relatively small size of the analyzed study 
group with allergies (>35  years old) could explain these 
Table 3 Socioeconomic factors (SEP) associated with  can-
cer diagnosis, allergy and  their combination—odds ratio 
in  comparison to  control patients without  diagnosis 
of cancer and/or allergy
All italic values are significant for p < 0.05
OR odds ratio, CI confidence interval








 Low 1.75 (0.89–1.32) 0.99 (0.76–1.31) 1.17 (0.98–1.54)
 Middle/high 1.23 (0.97–1.76) 1.87 (0.66–2.03) 1.34 (1.04–1.83)
Alcohol
 Never 1.37 (0.92–1.77) 0.93 (0.56–1.20) 0.73 (0.34–1.06)
 Occasionally 1.28 (0.88–1.96) 1.14 (0.85–1.79) 1.06 (0.78–1.37)
 Frequently 1.94 (1.03–2.43) 1.09 (0.78–1.53) 1.13 (0.67–1.54)
Smoking
 Never 0.76 (0.32–1.09) 1.06 (0.56–1.34) 0.81 (0.55–1.21)
 Past 1.97 (1.32–3.01) 1.01 (0.49–1.46) 1.64 (1.12–2.09)
 Current 2.09 (1.78–3.54) 1.27 (0.99–1.96) 1.97 (1.88–2.87)
Financial problems
 Yes 1.66 (1.10–2.13) 1.31 (0.84–1.81) 1.27 (0.97–1.66)
 No 1.41 (1.22–1.73) 1.09 (0.82–1.65) 1.15 (0.69–1.41)
BMI
 <30 kg/m2 1.21 (0.78–1.79) 1.13 (0.55–1.63) 1.22 (0.87–1.45)
 ≥30 kg/m2 1.39 (0.89–1.87) 1.05 (0.67–1.32) 1.01 (0.67–1.33)
Sex
 Women 1.11 (0.71–1.38) 1.41 (1.21–1.58) 1.18 (0.82–1.88)
 Men 1.28 (0.71–1.94) 2.08 (1.88–2.73) 1.41 (0.68–1.91)
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differences. Unfortunately, the applied restrictions for 
age do not permit an adequate assessment of the rela-
tionship between atopy and age. In contrast, the patients 
with cancer included in this study included a significantly 
higher number of current or past smokers than those in 
the control group, which explains their greater propen-
sity toward cancer. This finding have been repeatedly 
proven [29, 30].
This study was limited by a restricted number of 
patients and by the analyses of only certain types of can-
cers. The final number of patients analyzed was also sig-
nificant reduced due to the exclusion of patients during 
cancer treatment. However, this likely resulted in more 
reliable diagnostic results of allergy, particularly IgE, 
which was measured once. We worried that the concen-
trations of total and specific IgE in the patient serum dur-
ing oncological therapy could be underestimated because 
of its immunosuppressive effect, and this influence cannot 
be completely excluded. A relationship between IgE and 
oncological therapy in such patients was not observed.
The assessment of allergies in patients with cancer 
diagnoses is complicated and affected by a number of 
factors. Patients and physicians are typically focused on 
addressing the underlying disease, i.e., cancer. Therefore, 
in some of the analyzed patients, the diagnosis of allergy 
was overlooked because of other clinical symptoms.
Furthermore, in addition to skin cancers, we selectively 
examined the most prevalent types of cancers in the 
country. Skin cancers were included in our analyses due 
to the frequency with which skin cancers were observed 
to coincide with atopic dermatitis, as has been reported 
in the literature [9, 20, 31]. Our findings confirmed a 
weak, inverse, and proportional dependence [11].
The influence of oncologic therapies, such as chemo-
therapy and radiation therapy, could not be excluded 
from influencing the results of the allergy tests (i.e., false 
negatives). There were no analyses for IgE-mediated food 
allergies because of the relative rarity in adults. A small 
number of positive skin-prick test results and allergen-
specific IgEs to foods in the treatment groups resulted in 
their removal from the final analysis. Finally, the control 
group was obtained from GP sites, whereas the study 
patients were obtained from outpatient oncology clin-
ics; although the distributions of age and sex were simi-
lar between the two groups, this difference in source 
may be an important confounder (lack of uniform data, 
richer medical documentation due to greater attention to 
patients with cancer).
Conclusion
The observed association may indicate a dependence 
between IgE-mediated allergies and reduced prevalence 
of select types of cancers. In particular, the prevalence 
of allergic rhinitis was low among oncological study 
patients. Further studies are needed to confirm our 
findings.
Additionally, patients with cancer have mostly low 
socioeconomic status compared to those with allergy.
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